Skip to main content
Erschienen in: International Journal of Clinical Pharmacy 6/2008

01.12.2008 | Research Article

Using the costs of drug therapy to screen patients for a community pharmacy-based medication review program

verfasst von: Jean-Marc Krähenbühl, Anne Decollogny, Olivier Bugnon

Erschienen in: International Journal of Clinical Pharmacy | Ausgabe 6/2008

Einloggen, um Zugang zu erhalten

Abstract

Objectives To measure the positive predictive value (PPV) of the cost of drug therapy (threshold = 2000 Swiss francs [CHF], US$1440, €1360) as a screening criterion for identifying patients who may benefit from medication review (MR). To describe identified drug-related problems (DRPs) and expense problems (EPs), and to estimate potential savings if all recommendations were accepted. Setting Five voluntary Swiss community pharmacies. Methods Of 12,680 patients, 592 (4.7%) had drug therapy costs exceeding 2000 CHF over a six-month period from July 1 to December 31, 2002. This threshold limit was set to identify high-risk patients for DRPs and EPs. Three pharmacists consecutively conducted a medication review based on the pharmaceutical charts of 125 sampled patients who met the inclusion criterion. Main outcome measure The PPV of a threshold of 2000 CHF for identifying patients who might benefit from a MR: true positives were patients with at least one DRP, while false positives were patients with no DRP. Results The selection based on this criterion had a PPV of 86% for detecting patients with at least one DRP and 95% if EPs were also considered. There was a mean of 2.64 (SD = 2.20) DRPs per patient and a mean of 2.14 (SD = 1.39) EPs per patient. Of these patients, 90% were over 65 years old or were treated with at least five chronic medications, two common criteria for identifying patients at risk of DRPs. The main types of DRPs were drug–drug interactions, compliance problems and duplicate drugs. Mean daily drug cost per patient was CHF 14.87 (US$10.70, €10.10). A potential savings of CHF 1.67 (US$1.20, €1.14) per day (11%) was estimated if all recommendations to solve DRPs and EPs suggested herein were implemented. Conclusion Further studies should investigate whether the potential benefit of medication reviews in preventing DRPs and containing costs in this patient group can be confirmed in a real practice environment
Fußnoten
1
In Switzerland, pharmacists are mainly paid by a fixed remuneration fee, making their income only slightly dependent on the ex-factory price of the drug.
 
Literatur
1.
Zurück zum Zitat De Smet PA, Dautzenberg M. Repeat prescribing: scale, problems and quality management in ambulatory care patients. Drugs. 2004;64(16):1779–800.PubMedCrossRef De Smet PA, Dautzenberg M. Repeat prescribing: scale, problems and quality management in ambulatory care patients. Drugs. 2004;64(16):1779–800.PubMedCrossRef
2.
Zurück zum Zitat Britton ML, Lurvey PL. Impact of medication profile review on prescribing in a general medicine clinic. Am J Hosp Pharm. 1991;48(2):265–70.PubMed Britton ML, Lurvey PL. Impact of medication profile review on prescribing in a general medicine clinic. Am J Hosp Pharm. 1991;48(2):265–70.PubMed
3.
Zurück zum Zitat Zermansky AG, Petty DR, Raynor DK, Freemantle N, Vail A, Lowe CJ. Randomised controlled trial of clinical medication review by a pharmacist of elderly patients receiving repeat prescriptions in general practice. BMJ. 2001;323(7325):1340–3.PubMedCrossRef Zermansky AG, Petty DR, Raynor DK, Freemantle N, Vail A, Lowe CJ. Randomised controlled trial of clinical medication review by a pharmacist of elderly patients receiving repeat prescriptions in general practice. BMJ. 2001;323(7325):1340–3.PubMedCrossRef
4.
Zurück zum Zitat Grymonpre RE, Williamson DA, Morgan JD. Impact of a pharmaceutical care model for non-institutionalised elderly: results of a randomised, controlled trial. Int J Pharm Pract. 2001;9:235–41. Grymonpre RE, Williamson DA, Morgan JD. Impact of a pharmaceutical care model for non-institutionalised elderly: results of a randomised, controlled trial. Int J Pharm Pract. 2001;9:235–41.
5.
Zurück zum Zitat Krska J, Cromarty JA, Arris F, Jamieson D, Hansford D, Duffus PR, et al. Pharmacist-led medication review in patients over 65: a randomized, controlled trial in primary care. Age Ageing. 2001;30(3):205–11.PubMedCrossRef Krska J, Cromarty JA, Arris F, Jamieson D, Hansford D, Duffus PR, et al. Pharmacist-led medication review in patients over 65: a randomized, controlled trial in primary care. Age Ageing. 2001;30(3):205–11.PubMedCrossRef
6.
Zurück zum Zitat Read RW, Krska J. Targeted medication review: patients in the community with chronic pain. Int J Pharm Pract. 1998;6:216–22. Read RW, Krska J. Targeted medication review: patients in the community with chronic pain. Int J Pharm Pract. 1998;6:216–22.
7.
Zurück zum Zitat Bond C, Matheson C, Williams S, Williams P, Donnan P. Repeat prescribing: a role for community pharmacists in controlling and monitoring repeat prescriptions. Br J Gen Pract. 2000;50(453):271–5.PubMed Bond C, Matheson C, Williams S, Williams P, Donnan P. Repeat prescribing: a role for community pharmacists in controlling and monitoring repeat prescriptions. Br J Gen Pract. 2000;50(453):271–5.PubMed
8.
Zurück zum Zitat Borgsdorf LR, Miano JS, Knapp KK. Pharmacist-managed medication review in a managed care system. Am J Hosp Pharm. 1994;51(6):772–7.PubMed Borgsdorf LR, Miano JS, Knapp KK. Pharmacist-managed medication review in a managed care system. Am J Hosp Pharm. 1994;51(6):772–7.PubMed
9.
Zurück zum Zitat Holland R, Lenaghan E, Harvey I, Smith R, Shepstone L, Lipp A, et al. Does home based medication review keep older people out of hospital? The HOMER randomised controlled trial. BMJ. 2005;330(7486):293.PubMedCrossRef Holland R, Lenaghan E, Harvey I, Smith R, Shepstone L, Lipp A, et al. Does home based medication review keep older people out of hospital? The HOMER randomised controlled trial. BMJ. 2005;330(7486):293.PubMedCrossRef
10.
Zurück zum Zitat Hanlon JT, Lindblad CI, Gray SL. Can clinical pharmacy services have a positive impact on drug-related problems and health outcomes in community-based older adults? Am J Geriatr Pharmacother. 2004;2(1):3–13.PubMedCrossRef Hanlon JT, Lindblad CI, Gray SL. Can clinical pharmacy services have a positive impact on drug-related problems and health outcomes in community-based older adults? Am J Geriatr Pharmacother. 2004;2(1):3–13.PubMedCrossRef
11.
Zurück zum Zitat Jano E, Aparasu RR. Healthcare outcomes associated with beers’ criteria: a systematic review. Ann Pharmacother. 2007;41(3):438–47. Jano E, Aparasu RR. Healthcare outcomes associated with beers’ criteria: a systematic review. Ann Pharmacother. 2007;41(3):438–47.
12.
Zurück zum Zitat Hanlon JT, Weinberger M, Samsa GP, Schmader KE, Uttech KM, Lewis IK, et al. A randomized, controlled trial of a clinical pharmacist intervention to improve inappropriate prescribing in elderly outpatients with polypharmacy. Am J Med. 1996;100(4):428–37.PubMedCrossRef Hanlon JT, Weinberger M, Samsa GP, Schmader KE, Uttech KM, Lewis IK, et al. A randomized, controlled trial of a clinical pharmacist intervention to improve inappropriate prescribing in elderly outpatients with polypharmacy. Am J Med. 1996;100(4):428–37.PubMedCrossRef
13.
Zurück zum Zitat Zarowitz BJ, Stebelsky LA, Muma BK, Romain TM, Peterson EL. Reduction of high-risk polypharmacy drug combinations in patients in a managed care setting. Pharmacotherapy. 2005;25(11):1636–45.PubMedCrossRef Zarowitz BJ, Stebelsky LA, Muma BK, Romain TM, Peterson EL. Reduction of high-risk polypharmacy drug combinations in patients in a managed care setting. Pharmacotherapy. 2005;25(11):1636–45.PubMedCrossRef
14.
Zurück zum Zitat Guignard E, Bugnon O. Pharmaceutical care in community pharmacies: practice and research in Switzerland. Ann Pharmacother. 2006;40(3):512–7.PubMedCrossRef Guignard E, Bugnon O. Pharmaceutical care in community pharmacies: practice and research in Switzerland. Ann Pharmacother. 2006;40(3):512–7.PubMedCrossRef
16.
Zurück zum Zitat Hanlon JT, Schmader KE, Samsa GP, Weinberger M, Uttech KM, Lewis IK, et al. A method for assessing drug therapy appropriateness. J Clin Epidemiol. 1992;45(10):1045–51PubMedCrossRef Hanlon JT, Schmader KE, Samsa GP, Weinberger M, Uttech KM, Lewis IK, et al. A method for assessing drug therapy appropriateness. J Clin Epidemiol. 1992;45(10):1045–51PubMedCrossRef
17.
Zurück zum Zitat Allard J, Hebert R, Rioux M, Asselin J, Voyer L. Efficacy of a clinical medication review on the number of potentially inappropriate prescriptions prescribed for community-dwelling elderly people. CMAJ. 2001;164(9):1291–6. PubMed Allard J, Hebert R, Rioux M, Asselin J, Voyer L. Efficacy of a clinical medication review on the number of potentially inappropriate prescriptions prescribed for community-dwelling elderly people. CMAJ. 2001;164(9):1291–6. PubMed
18.
Zurück zum Zitat Howard RL, Avery AJ, Slavenburg S, Royal S, Pipe G, Lucassen P, et al. Which drugs cause preventable admissions to hospital? A systematic review. Br J Clin Pharmacol. 2007;63(2):136–47.PubMedCrossRef Howard RL, Avery AJ, Slavenburg S, Royal S, Pipe G, Lucassen P, et al. Which drugs cause preventable admissions to hospital? A systematic review. Br J Clin Pharmacol. 2007;63(2):136–47.PubMedCrossRef
19.
Zurück zum Zitat Sadik A, Yousif M, McElnay JC. Pharmaceutical care of patients with heart failure. Br J Clin Pharmacol. 2005;60(2):183–93.PubMedCrossRef Sadik A, Yousif M, McElnay JC. Pharmaceutical care of patients with heart failure. Br J Clin Pharmacol. 2005;60(2):183–93.PubMedCrossRef
20.
Zurück zum Zitat Wermeille J, Bennie M, Brown I, McKnight J. Pharmaceutical care model for patients with type 2 diabetes: integration of the community pharmacist into the diabetes team–a pilot study. Pharm World Sci. 2004;26(1):18–25.PubMedCrossRef Wermeille J, Bennie M, Brown I, McKnight J. Pharmaceutical care model for patients with type 2 diabetes: integration of the community pharmacist into the diabetes team–a pilot study. Pharm World Sci. 2004;26(1):18–25.PubMedCrossRef
21.
Zurück zum Zitat Ruths S, Straand J, Nygaard HA. Multidisciplinary medication review in nursing home residents: what are the most significant drug-related problems? The Bergen District Nursing Home (BEDNURS) study. Qual Saf Health Care. 2003;12(3):176–80.PubMedCrossRef Ruths S, Straand J, Nygaard HA. Multidisciplinary medication review in nursing home residents: what are the most significant drug-related problems? The Bergen District Nursing Home (BEDNURS) study. Qual Saf Health Care. 2003;12(3):176–80.PubMedCrossRef
22.
Zurück zum Zitat Fialova D, Topinkova E, Gambassi G, Finne-Soveri H, Jonsson PV, Carpenter I, et al. Potentially inappropriate medication use among elderly home care patients in Europe. JAMA. 2005;293(11):1348–58.PubMedCrossRef Fialova D, Topinkova E, Gambassi G, Finne-Soveri H, Jonsson PV, Carpenter I, et al. Potentially inappropriate medication use among elderly home care patients in Europe. JAMA. 2005;293(11):1348–58.PubMedCrossRef
23.
Zurück zum Zitat Odera GM, Gunning K, LaFleur J, Stockdale W, Tyler L, Parke D, et al. Reviews of Utah Medicaid high utilizers to control drug costs. Value Health. 2003;6(3):206. Odera GM, Gunning K, LaFleur J, Stockdale W, Tyler L, Parke D, et al. Reviews of Utah Medicaid high utilizers to control drug costs. Value Health. 2003;6(3):206.
24.
Zurück zum Zitat Viktil KK, Blix HS, Moger TA, Reikvam A. Polypharmacy as commonly defined is an indicator of limited value in the assessment of drug-related problems. Br J Clin Pharmacol. 2007;63(2):187–95.PubMedCrossRef Viktil KK, Blix HS, Moger TA, Reikvam A. Polypharmacy as commonly defined is an indicator of limited value in the assessment of drug-related problems. Br J Clin Pharmacol. 2007;63(2):187–95.PubMedCrossRef
25.
Zurück zum Zitat Krass I, Smith C. Impact of medication regimen reviews performed by community pharmacists for ambulatory patients through liaison with general medical practitioners. Int J Pharm Pract. 2000;8:111–20. Krass I, Smith C. Impact of medication regimen reviews performed by community pharmacists for ambulatory patients through liaison with general medical practitioners. Int J Pharm Pract. 2000;8:111–20.
26.
Zurück zum Zitat McDermott ME, Smith BH, Elliott AM, Bond CM, Hannaford PC, Chambers WA. The use of medication for chronic pain in primary care, and the potential for intervention by a practice-based pharmacist. Fam Pract. 2006;23(1):46–52.PubMedCrossRef McDermott ME, Smith BH, Elliott AM, Bond CM, Hannaford PC, Chambers WA. The use of medication for chronic pain in primary care, and the potential for intervention by a practice-based pharmacist. Fam Pract. 2006;23(1):46–52.PubMedCrossRef
27.
Zurück zum Zitat Petty D, Knapp P, Raynor DK, Zermansky AG, Freemantle N. Clinical medication review in general practice: what is the benefit of a second review? Int J Pharm Pract. 2002;10(suppl):R70. Petty D, Knapp P, Raynor DK, Zermansky AG, Freemantle N. Clinical medication review in general practice: what is the benefit of a second review? Int J Pharm Pract. 2002;10(suppl):R70.
Metadaten
Titel
Using the costs of drug therapy to screen patients for a community pharmacy-based medication review program
verfasst von
Jean-Marc Krähenbühl
Anne Decollogny
Olivier Bugnon
Publikationsdatum
01.12.2008
Verlag
Springer Netherlands
Erschienen in
International Journal of Clinical Pharmacy / Ausgabe 6/2008
Print ISSN: 2210-7703
Elektronische ISSN: 2210-7711
DOI
https://doi.org/10.1007/s11096-008-9232-5

Weitere Artikel der Ausgabe 6/2008

International Journal of Clinical Pharmacy 6/2008 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.